A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/04/2004	WO2004093827A2 Phenolic acid salts of gabapentin in solid dosage forms and methods of use
11/04/2004	WO2004093826A2 Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
11/04/2004	WO2004093823A2 Polyethelene glycol link glp-1 compounds
11/04/2004	WO2004093821A2 Treatment of anthrax infection using inhibitors of lethal factor protease activity
11/04/2004	WO2004093817A2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/04/2004	WO2004093816A2 Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
11/04/2004	WO2004093814A2 Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
11/04/2004	WO2004093813A2 Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
11/04/2004	WO2004093812A2 Compounds that induce neuronal differentiation in embryonic stem cells
11/04/2004	WO2004093811A2 Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
11/04/2004	WO2004093809A2 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
11/04/2004	WO2004093805A2 Selective spirocyclic glucocorticoid receptor modulators
11/04/2004	WO2004093802A2 Prevention of deficits in neurogenesis with anti-inflammatory agents
11/04/2004	WO2004093801A2 Pharmaceutical products
11/04/2004	WO2004093800A2 Thyronamine derivatives and analogs and methods of use thereof
11/04/2004	WO2004093799A2 Thyroid receptor ligands
11/04/2004	WO2004093798A2 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
11/04/2004	WO2004093795A2 Compositions for delivery of drug combinations
11/04/2004	WO2004093794A2 Antimicrobial medical articles containing a combination of anti-infective compounds, octoxyclycerin, salicylic acid, and sesquiterpenoids
11/04/2004	WO2004093792A2 Compositions and methods for treating body malodor and fungal overgrowth in mammals
11/04/2004	WO2004093790A2 Yeast ectopically expressing abnormally processed proteins and uses therefor
11/04/2004	WO2004093789A2 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
11/04/2004	WO2004093788A2 Desmoglein 4 is a novel gene involved in hair growth
11/04/2004	WO2004093781A2 Podophyllotoxin derivatives as igf-1r inhibitors
11/04/2004	WO2004093722A2 Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
11/04/2004	WO2004093664A2 Method and kit for controlling bleeding
11/04/2004	WO2004093650A2 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid
11/04/2004	WO2004087673A3 Migrastatin analogs and uses thereof
11/04/2004	WO2004084826A3 Antifungal nail coat and method of use
11/04/2004	WO2004083215A3 Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
11/04/2004	WO2004083185A3 Phenyl substituted imidazole derivatives
11/04/2004	WO2004082589A3 Nasally administrable, bioavailable pharmaceutical composition of loratadine
11/04/2004	WO2004082584A3 5ht2c receptor antagonists in the treatment of schizophrenia
11/04/2004	WO2004082577A3 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
11/04/2004	WO2004080951A3 Sulfonic acids, their derivatives and pharmaceutical compositions containing them
11/04/2004	WO2004080423A3 7-amino- isoindolyl compounds amd their pharmaceutical uses
11/04/2004	WO2004080271A3 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
11/04/2004	WO2004078747A8 Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
11/04/2004	WO2004076349B1 Therapeutic malonic acid/acetic acid c60 tri-adducts of buckminsterfullerene and methods related thereto
11/04/2004	WO2004074812A3 Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/04/2004	WO2004074450A8 Combination therapy for treating protein deficiencies
11/04/2004	WO2004074248A3 Isolation and structure of cribrostatin 6
11/04/2004	WO2004073703B1 Glycinamide derivative for inhibiting hiv replication
11/04/2004	WO2004071463A3 Fluoromethotrexates and uses therefor
11/04/2004	WO2004071271A3 Improving fetal physiology during maternal surgery or diagnosis
11/04/2004	WO2004069794A3 New arylpiperazinyl compounds
11/04/2004	WO2004069254A3 Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
11/04/2004	WO2004069232A3 Egfr tyrosine kinase inhibitor for treating cardiovascular dysfunction
11/04/2004	WO2004069192A3 Material and method for treating microbial mediated dermatological conditions
11/04/2004	WO2004069143A3 Treatment of inflammatory bowel disease
11/04/2004	WO2004067506A3 Substituted heterocyclic compounds
11/04/2004	WO2004067498A3 Aryl alkyl carbamate derivatives production and use thereof in therapy
11/04/2004	WO2004067480A3 Substituted phenylurea derivatives as hdac inhibitors
11/04/2004	WO2004067063A3 Improved formulations for transmucosal vaginal delivery of bisphosphonates
11/04/2004	WO2004066990A3 Methods of treating lower urinary tract disorders using sodium channel modulators
11/04/2004	WO2004066987A3 Use of sodium channel modulators for treating gastrointestinal tract disorders
11/04/2004	WO2004062653A3 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
11/04/2004	WO2004062613A3 Hiv integrase inhibitors
11/04/2004	WO2004062596A3 Antineoplastic ether lipid compounds having a four carbon backbone
11/04/2004	WO2004061084A3 Modulation of protein functionalities
11/04/2004	WO2004060319A3 Immunostimulatory combinations
11/04/2004	WO2004060286A3 Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
11/04/2004	WO2004058139A3 Use of istradefylline (kw-6002) for the treatment of behavioral disorders
11/04/2004	WO2004056353A3 Device and method for delivering mmp inhibitors
11/04/2004	WO2004055154A3 Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness
11/04/2004	WO2004053192A9 Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
11/04/2004	WO2004050681A3 Kinase modulators
11/04/2004	WO2004045592A3 Compounds and methods for increasing neurogenesis
11/04/2004	WO2004043387A3 Compositions and methods for cancer diagnosis and therapy
11/04/2004	WO2004043340A3 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
11/04/2004	WO2004042351A3 Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
11/04/2004	WO2004041215A3 Methods for treating gastroesophageal reflux disease
11/04/2004	WO2004035798A3 Identification of e2f target genes and uses thereof
11/04/2004	WO2004034996A3 TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING α 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING
11/04/2004	WO2004032853A3 Compositions and methods for treating sexual dysfunction
11/04/2004	WO2004026259A3 Transdermal compositions
11/04/2004	WO2004024069A9 Novel compositions and methods for the treatment of immune-related diseases
11/04/2004	WO2004012687A3 Crystalline and amorphous forms of beta-l-2'-deoxythymidine
11/04/2004	WO2004009035A3 Compositions and products containing enantiomeric equol, and methods for their making
11/04/2004	WO2004004652A3 Mitotic kinesin binding site
11/04/2004	WO2004003000A3 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
11/04/2004	WO2003103662A3 Inhibitors of glycoprotein vi
11/04/2004	WO2003102135A3 Control sequences of the human corin gene
11/04/2004	WO2003091403A3 Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases
11/04/2004	WO2003090753A8 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
11/04/2004	WO2003090512A3 Regeneration of endogenous myocardial tissue by induction of neovascularization
11/04/2004	WO2003086324A3 Preparation and use of a stable formulation of allosteric effector compounds
11/04/2004	WO2003082867A8 Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
11/04/2004	WO2003078431A8 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
11/04/2004	WO2003077847A3 Substituted amides
11/04/2004	WO2003076593A3 Genomic screen for epigenetically silenced genes associated with cancer
11/04/2004	WO2003000183A3 Method of treating atherosclerosis and other inflammatory diseases
11/04/2004	WO1999029693A8 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
11/04/2004	US20040220568 Method for lateral implantation of spinous process spacer
11/04/2004	US20040220536 Apparatus with weeping tip and method of use
11/04/2004	US20040220408 As anti-proliferative agents, therapy
11/04/2004	US20040220403 For therapy and prophylaxis of Tachykinin-mediated diseases
11/04/2004	US20040220402 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
11/04/2004	US20040220399 Useful for inhibiting beta -lactamase enzymes, for enhancing the activity of beta -lactam antibiotics, and for treating beta -lactam resistant bacterial infections in a mammal
11/04/2004	US20040220392 Compositions for, and methods of, treating atherosclerosis

1 ... 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 ... 7860